Heart Health

Medically reviewed by Dr. Kimberly Langdon Cull, M.D. on July 25, 2023 There is a significant association between non-alcoholic fatty liver disease and an increased prevalence of early-onset vasomotor symptoms in premenopausal women. Vasomotor symptoms are prevalent among women undergoing menopausal transition and are also associated with poor quality of life, metabolic disruption, and increased...

Medically reviewed by Dr. Kimberly Langdon Cull, M.D. on July 25, 2023 The vasomotor symptoms associated with menopause tend to affect women’s quality of life, sleep, and mood. Poor symptom control, treatment dissatisfaction, and negative perceptions of hormone therapy necessitate the implementation of improved management measures.   A substantial percentage of postmenopausal and perimenopausal women experience...

Heart disease is a terrifying medical issue that kills around 697,000 Americans each year. Because of this, preventing heart disease is a top issue for many.  However, the possibility of a genetic condition adds a hurdle to this. If heart disease is genetic, can it truly be managed?  This article will explore the genetic nature...

Heart disease is one of the leading causes of death for adults in America and is something many people live with for the rest of their lives. With this in mind, it is understandable to question if it can be reversed. After all, the ability to do so would dramatically improve lives while simultaneously improving...

Diagnosing ATTR-CM is usually a difficult and potentially dangerous process, but non-invasive novel modalities could significantly reduce the risk. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease characterized by deposits of amyloid fibrils. It tends to have high morbidity, poor treatment outcomes, and high treatment expenditure. Recent advances in therapeutic strategies for ATTR-CM have shown...

ATTR-CM can only be treated in a limited number of ways, and this article analyzes and compares the currently available treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating disease with high mortality. ATTR-CM is caused by transthyretin (TTR) amyloid protein build ups in the myocardium and other organs, in most cases the peripheral...

With a minimal incidence of amyloid recurrence in the cardiac allograft, cardiac transplantation is well tolerated, increases functional ability, and lengthens survival in patients with ATTR-CM, according to a 30-year retrospective study. ATTR-CM should be included in the list of transplantation indications. Cardiomyopathy caused by transthyretin amyloidosis cardiomyopathy (ATTR-CM) is progressive and fatal. Patients with...

In patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), tafamidis was associated with a lower rate of CV-related hospitalizations and a shorter stay. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underdiagnosed disease characterized by deposits of improperly folded transthyretin amyloid fibrils, resulting in end-organ dysfunction. ATTR-CM patients present with symptoms of invasive cardiomyopathy and heart failure necessitating expensive...

Emboli are a common complication of amyloid transthyretin cardiomyopathy (ATTR-CM). This study found that the CHA2DS2-VASc score is not useful in predicting embolic events in ATTR-CM patients with or without AF, and that VKAs and DOACs are equally effective in preventing embolism, in this scenario. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative illness with a...